GO
| HSI1 | 26,095.05 | +61.79 | 178.25B |
| HSCEI1 | 9,182.65 | +9.81 | 71.67B |
| Back Zoom + Zoom - Block Traded | |
|
2025-12-02 14:49:08 In May, UBS downgraded ALI HEALTH (00241.HK)'s rating, but since then ALI HEALTH's first-party platform sales growth has surpassed its forecasts, according to its research report. UBS attributed this performance to a structural shift from offline to online pharmaceutical supply rather than a strategic pivot towards first-party platforms or first-party pharmaceutical sales. The broker also believes that leading peers can profit early from this structural trend. ALI HEALTH's target price has been raised from HKD3.8 to HKD4.7, with a Sell rating remaining in place. ~ AAStocks Financial News Web Site: www.aastocks.com | |